Jiangsu Yahong Meditech Co., Ltd. Class A 688176
SSE · China · Health Technology
CNY 14.60+0.85 (+6.18%)
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CNY · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The 19th World Congress of the International Federation for Cervical Pathology and Colposcopy (IFCPC) took place in Paris, France, in 2026. Held concurrently was an international expert consensus symposium on the standardized application of topical photodynamic therapy (PDT) for cervical precancerous lesions, with involvement from Asieris Pharmaceuticals. Leading gynecologic oncologists and colposcopists from the United States, Europe, and China gathered to engage in in-depth discussions on core
Asieris Pharmaceuticals (Stock Code: 688176.SH), a global innovative pharmaceutical company focused on genitourinary tumors and women's health, announced today that its core product APL-1702 (trade name: CEVIRA®, Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System), has received the Drug Registration Certificate from China's National Medical Products Administration (NMPA) for its commercial launch. As the world's first non-surgical, non-invasive therapy for patients with cervic
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.